טוען...
Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs
We surveyed availability of phenotypic drug susceptibility testing for drug-resistant Mycobacterium tuberculosis in Europe. Of 27 laboratories, 17 tested for linezolid, 11 for clofazimine, 9 for bedaquiline, and 6 for delamanid during 2019. Our findings indicate that testing capacity for newer and r...
שמור ב:
| הוצא לאור ב: | Emerg Infect Dis |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Centers for Disease Control and Prevention
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7920658/ https://ncbi.nlm.nih.gov/pubmed/33622487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3201/eid2703.204418 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|